JNJ
Johnson & Johnson
$272.00
0.54 (0.20%) Today
0.78 (0.29%) After-hours
— up— down
Market Cap
$653.61B+50.9%
Revenue (TTM)
$96.72B+8.1%
Net Income (TTM)
$20.78B-7.8%
EPS (TTM)
8.62-7.8%
Shares Out
2.41B
2.41BP/E Ratio
30.97
30.97Forward P/E
21.98
21.98Dividend
$5.14 (3.12%)
$5.14 (3.12%)Ex-Dividend Date
Aug 25, 2026
Aug 25, 2026Open
$271.22
$271.22Previous Close
$270.68
$270.68Day Range
$269.26 – $272.25
$269.26 – $272.2552-Week Range
$179.80 – $281.07
$179.80 – $281.07Beta
0.21
0.21Volume
4.06M
4.06MAvg Volume
7.59M
7.59MAnalyst Rating
Buy
BuyExchange
NEW YORK STOCK EXCHANGE, INC.
NEW YORK STOCK EXCHANGE, INC.About JNJ
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
Related
News
N/AN/AN/AN/AN/A
What Does Johnson & Johnson (JNJ) New Clinical Data Mean For Its Stock?
Yahoo · 17h ago
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo · 1d ago
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
Yahoo · 1d ago
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Yahoo · 1d ago
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Yahoo · 1d ago